MURA•benzinga•
Mural Oncology Highlights Clinical Antitumor Activity Of Lead Candidate Nemvaleukin In Published ARTISTRY-1 Trial Data, Supporting Registrational Trials With Readouts Expected In 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 20, 2024 by benzinga